Press-release for stocks related to covid for ocgn

Prices are updated after-hours

tags : Covid symbols : Ocgn

save search

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Published: 2022-02-18 (Crawled : 23:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| Email alert Add to watchlist
covid-19 clinical hold new drug fda bbv152 application xin drug covid vaccine submission

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options
Published: 2022-02-15 (Crawled : 12:30) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -56.32% | O: 3.16% H: 3.86% C: 3.86%
covid-19 america covid vaccine

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS
Published: 2021-12-30 (Crawled : 15:30) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -63.7% | O: -4.79% H: 21.34% C: 15.83%
bbv152 covid-19 xin covid positive children biotech vaccine iot

New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -66.94% | O: 5.61% H: 9.84% C: 6.69%
bbv152 covid-19 xin covid vaccine

Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Published: 2021-11-26 (Crawled : 12:30) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -77.61% | O: -15.49% H: 19.5% C: 7.5%
bbv152 covid new drug fda application xin vaccine drug phase 3 trial clinical hold

Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
Published: 2021-11-05 (Crawled : 11:00) - biospace.com/
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -84.19% | O: 0.5% H: 4.35% C: 1.29%
covid fda children vaccine merge submission bbv152 emergency use authorization

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Published: 2021-10-27 (Crawled : 11:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -82.62% | O: 0.44% H: 7.18% C: 4.57%
covid new drug fda application vaccine drug phase 3 trial submission bbv152

Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
Published: 2021-07-02 (Crawled : 22:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| Email alert Add to watchlist
covid disease results biotech vaccine phase 3 iot

COVID-19 News: Ocugen Secures Manufacturing, Ampio Stops Study and More
Published: 2021-06-15 (Crawled : 17:00) - biospace.com/
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -74.06% | O: 15.5% H: 3.81% C: -11.58%
COCP | $1.4 -3.45% -3.57% 22K

Health Technology

| 2.77% | O: -2.92% H: 2.17% C: -3.01%
AMPE | $0.62 0.0% 53K

Health Technology

| -65.56% | O: 6.11% H: 3.66% C: -1.05%
covid covid-19

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™Jubilant HollisterStier to manufacture COVAXIN™ in the US
Published: 2021-06-15 (Crawled : 12:15) - biospace.com/
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -74.06% | O: 15.5% H: 3.81% C: -11.58%
covid partnership vaccine

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
Published: 2021-06-15 (Crawled : 12:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -74.06% | O: 15.5% H: 3.81% C: -11.58%
covid partnership vaccine covid-19

Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -82.92% | O: -26.53% H: 16.96% C: -2.19%
covid vaccine covid-19

Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™
Published: 2021-05-27 (Crawled : 01:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -79.24% | O: 0.91% H: 13.32% C: 12.68%
covid fda vaccine merge authorized application emergency use authorization

Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization
Published: 2021-04-21 (Crawled : 14:00) - biospace.com/
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -71.2% | O: 20.47% H: 1.65% C: -2.26%
covid disease results biotech vaccine iot

Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development
Published: 2021-03-29 (Crawled : 13:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M

Health Technology

| -77.7% | O: -2.1% H: 0.29% C: -6.88%
covid vaccine

Ocugen to Seek EUA for India-Developed COVID Vaccine in the United States
Published: 2021-03-17 (Crawled : 16:00) - biospace.com/
JNJ | $147.59 0.05% 0.0% 8.5M

Health Technology